The efficacy of teneligliptin in diabetic patients on hemodialysis

The efficacy of teneligliptin in diabetic patients on hemodialysis - The efficacy of teneligliptin in diabetic patients on hemodialysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010999

Enrollment

Registered

2013-06-24

Start date

2013-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetic patients on hemodialysis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Fresh cases for DPP-4 inhibitor: Patients with poor glycemic control (HbA1c level exceeding 7.0% and/or glycated albumin level exceeding 21.0%) after two months on conventional therapy (dietary therapy alone or mitiglinide and/or alpha-glucosidase inhibitor). 2) Cases whose treatment is changed from other DPP-4 inhibitors: Patients have been treated with alogliptin.

Exclusion criteria

Exclusion criteria: Patients having infectious diseases, thyroid disease, or malignant tumors. Patients being treated with steroids.

Design outcomes

Primary

Measure	Time frame
The primary end-point is postprandial plasma glucose, glycated albumin or HbA1c measurement three months after new, additional administration of teneligliptin and change from alogliptin in type 2 diabetic patients on hemodialysis.	—

Secondary

Measure	Time frame
Other laboratory data, hemodialytic indices and adverse events will be analyzed as well.	—

Countries

Japan

Contacts

Public ContactAkiko Miyajima

Kawashima Hospital The general affairs division

a.miyajima@khg.or.jp088-631-0110

Outcome results